AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases.
Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C).
The company was founded in 2019 and is based in Naarden, the Netherlands.
Country | NL |
IPO Date | Feb 9, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 62 |
CEO | Dr. Michael Harvey Davidson FACC, Facp., M.D. |
Contact Details
Address: Gooimeer 2-35 Naarden, NL | |
Website | https://www.newamsterdampharma.com |
Stock Details
Ticker Symbol | NAMS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001936258 |
CUSIP Number | n/a |
ISIN Number | NL00150012L7 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Michael Harvey Davidson FACC, Facp., M.D. | Chief Executive Officer, President, Executive Board Member & Director |
Douglas F. Kling | Chief Operating Officer |
Mayur Amrat Somaiya | Chief Financial Officer |
Bob Rambo | Executive Vice President of Marketing |
Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director |
Dr. Marc Ditmarsch M.D. | Chief Development Officer |
Dr. Sheng Cui Ph.D. | Chief Manufacturing Officer |
Juliette Audet M.B.A., M.Sc. | Chief Business Officer |
Louise Kooij | Chief Accounting Officer |
Matthew Philippe | Executive Vice President &Head of Investor Relations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 10, 2025 | 8-K | Current Report |
Jan 08, 2025 | 4 | Filing |
Jan 08, 2025 | 4 | Filing |
Jan 08, 2025 | 4 | Filing |
Jan 08, 2025 | 4 | Filing |
Jan 08, 2025 | 4 | Filing |
Jan 07, 2025 | 4 | Filing |
Jan 07, 2025 | 4 | Filing |
Jan 07, 2025 | 4 | Filing |
Jan 07, 2025 | 4 | Filing |